IP Library › Granted Patent US 8,013,125
Granted Patent B2
US 8,013,125 · App. 12/397,285 · Granted Sep 6, 2011

Metalloproteinase 9 and metalloproteinase 2 binding proteins

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,013,125
App. No.
12/397,285
Granted
Sep 6, 2011
Kind
B2
Abstract

Proteins that bind to matrix metalloproteinase 9 and to matrix metalloproteinase 2 and methods of using such proteins are described.

Claims (4)

1. An isolated antibody that binds to human Matrix Metalloproteinase-9 (MMP-9) and human Matrix Metalloproteinase-2 (MMP-2), wherein the antibody comprises a heavy chain variable domain comprising a HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1289, a HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 1290, a HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 1291, and a light chain variable region comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1286, a LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 1287, and a LC-CDR3 region comprising the amino acid sequence of SEQ ID NO: 1288.

2. An anti-MMP-9/MMP-2 antibody-drug conjugate, wherein the conjugate comprises the isolated antibody of claim 1 and a drug.

3. The conjugate of claim 2 , wherein the drug is a cytotoxic or cytostatic agent.

4. A composition comprising the isolated antibody of claim 1 and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2021
From: DYAX CORP.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 056268/0983 →